$542 Million is the total value of NEXTHERA CAPITAL LP's 39 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 113.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | Buy | SPDR S&P Biotech ETFput | $169,740,000 | +30.7% | 2,000,000 | +33.3% | 31.29% | -6.3% |
| AGN | New | Allergan PLC | $34,004,000 | – | 207,871 | +100.0% | 6.27% | – |
| SHPG | Buy | Shire PLCsponsored adr | $25,122,000 | +135.5% | 161,949 | +132.5% | 4.63% | +68.8% |
| MYL | New | Mylan NV | $19,898,000 | – | 470,296 | +100.0% | 3.67% | – |
| MRK | New | Merck & Co Inc | $19,486,000 | – | 346,293 | +100.0% | 3.59% | – |
| BMY | New | Bristol-Myers Squibb Cocall | $18,114,000 | – | 295,600 | +100.0% | 3.34% | – |
| AZN | New | AstraZeneca PLCcall | $16,191,000 | – | 466,600 | +100.0% | 2.98% | – |
| ABLX | New | Ablynx NVsponsored adr | $15,941,000 | – | 637,884 | +100.0% | 2.94% | – |
| CLVS | Buy | Clovis Oncology Inccall | $15,858,000 | +449.9% | 233,200 | +566.3% | 2.92% | +294.1% |
| INSM | Buy | Insmed Inc | $15,556,000 | +246.2% | 498,921 | +246.5% | 2.87% | +148.1% |
| BMRN | Buy | BioMarin Pharmaceutical Inc | $14,624,000 | +31.3% | 163,997 | +37.1% | 2.70% | -5.9% |
| DOVA | Buy | Dova Pharmaceuticals Inc | $13,047,000 | +22.6% | 453,032 | +3.4% | 2.40% | -12.1% |
| GBT | Buy | Global Blood Therapeutics Inc | $12,258,000 | +46.2% | 311,516 | +15.3% | 2.26% | +4.8% |
| FLXN | New | Flexion Therapeutics Inccall | $11,681,000 | – | 466,500 | +100.0% | 2.15% | – |
| SGMO | Sell | Sangamo Therapeutics Inc | $11,620,000 | -0.8% | 708,544 | -9.3% | 2.14% | -28.9% |
| ALNY | Buy | Alnylam Pharmaceuticals Inc | $10,964,000 | +17.0% | 86,293 | +8.2% | 2.02% | -16.2% |
| FGEN | Sell | FibroGen Inc | $9,520,000 | -18.6% | 200,841 | -7.6% | 1.76% | -41.7% |
| BMRN | New | BioMarin Pharmaceutical Inccall | $9,238,000 | – | 103,600 | +100.0% | 1.70% | – |
| SAGE | New | Sage Therapeutics Inc | $9,196,000 | – | 55,834 | +100.0% | 1.70% | – |
| SCMP | New | Sucampo Pharmaceuticals Inccl a | $9,163,000 | – | 510,486 | +100.0% | 1.69% | – |
| ALXN | New | Alexion Pharmaceuticals Inccall | $8,658,000 | – | 72,400 | +100.0% | 1.60% | – |
| GLYC | Buy | GlycoMimetics Inc | $8,067,000 | +79.5% | 480,442 | +49.5% | 1.49% | +28.6% |
| MRNS | Buy | Marinus Pharmaceuticals Inc | $7,551,000 | +114.4% | 925,327 | +54.2% | 1.39% | +53.6% |
| KURA | Buy | Kura Oncology Inc | $6,817,000 | +76.4% | 445,550 | +72.3% | 1.26% | +26.5% |
| IMMU | Sell | Immunomedics Inc | $6,537,000 | -41.0% | 404,528 | -48.9% | 1.20% | -57.7% |
| ATRA | New | Atara Biotherapeutics Inc | $5,188,000 | – | 286,647 | +100.0% | 0.96% | – |
| CBAY | Buy | Cymabay Therapeutics Inc | $4,936,000 | +3979.3% | 536,568 | +3477.1% | 0.91% | +2835.5% |
| SPPI | New | Spectrum Pharmaceuticals Incput | $4,914,000 | – | 259,300 | +100.0% | 0.91% | – |
| CBIO | New | Catalyst Biosciences Inc | $4,244,000 | – | 311,175 | +100.0% | 0.78% | – |
| AVDL | New | Avadel Pharmaceuticals PLCsponsored adr | $4,149,000 | – | 505,921 | +100.0% | 0.76% | – |
| TSRO | TESARO Incput | $4,144,000 | -35.8% | 50,000 | 0.0% | 0.76% | -54.0% | |
| CTMX | New | CytomX Therapeutics Inc | $3,797,000 | – | 179,870 | +100.0% | 0.70% | – |
| OTIC | New | Otonomy Inc | $3,345,000 | – | 602,748 | +100.0% | 0.62% | – |
| TXMD | New | TherapeuticsMD Inc | $3,191,000 | – | 528,351 | +100.0% | 0.59% | – |
| ANIP | New | ANI Pharmaceuticals Inc | $2,701,000 | – | 41,905 | +100.0% | 0.50% | – |
| KALV | New | KalVista Pharmaceuticals Inc | $1,763,000 | – | 180,794 | +100.0% | 0.32% | – |
| ZFGN | New | Zafgen Inc | $792,000 | – | 171,435 | +100.0% | 0.15% | – |
| TGTX | New | TG Therapeutics Inc | $246,000 | – | 30,000 | +100.0% | 0.04% | – |
| VTGN | VistaGen Therapeutics Inc | $154,000 | -30.3% | 138,132 | 0.0% | 0.03% | -50.9% | |
| AVEO | Exit | AVEO Pharmaceuticals Inc | $0 | – | -52,000 | -100.0% | -0.05% | – |
| AXGT | Exit | Axovant Sciences Ltdcall | $0 | – | -40,000 | -100.0% | -0.07% | – |
| ZSAN | Exit | Zosano Pharma Corp | $0 | – | -375,809 | -100.0% | -0.08% | – |
| STDY | Exit | SteadyMed Ltd | $0 | – | -258,918 | -100.0% | -0.22% | – |
| MDGL | Exit | Madrigal Pharmaceuticals Inc | $0 | – | -28,536 | -100.0% | -0.33% | – |
| Exit | Intec Pharma Ltd | $0 | – | -276,324 | -100.0% | -0.64% | – | |
| RXDX | Exit | Ignyta Inc | $0 | – | -285,728 | -100.0% | -0.91% | – |
| NERV | Exit | Minerva Neurosciences Inc | $0 | – | -536,899 | -100.0% | -1.05% | – |
| ABEO | Exit | Abeona Therapeutics Inccall | $0 | – | -300,000 | -100.0% | -1.32% | – |
| SUPN | Exit | Supernus Pharmaceuticals Inc | $0 | – | -132,270 | -100.0% | -1.36% | – |
| PRTK | Exit | Paratek Pharmaceuticals Inc | $0 | – | -242,300 | -100.0% | -1.56% | – |
| FLXN | Exit | Flexion Therapeutics Inc | $0 | – | -271,136 | -100.0% | -1.69% | – |
| ARRY | Exit | Array BioPharma Inc | $0 | – | -615,437 | -100.0% | -1.95% | – |
| IPXL | Exit | Impax Laboratories Inc | $0 | – | -402,404 | -100.0% | -2.10% | – |
| ALXN | Exit | Alexion Pharmaceuticals Inc | $0 | – | -62,337 | -100.0% | -2.25% | – |
| AKAOQ | Exit | Achaogen Inc | $0 | – | -577,766 | -100.0% | -2.37% | – |
| ACRS | Exit | Aclaris Therapeutics Inc | $0 | – | -416,312 | -100.0% | -2.76% | – |
| GSK | Exit | GlaxoSmithKline PLCsponsored adr | $0 | – | -358,053 | -100.0% | -3.74% | – |
| CLVS | Exit | Clovis Oncology Inc | $0 | – | -184,680 | -100.0% | -3.92% | – |
| TEVA | Exit | Teva Pharmaceutical Industriesput | $0 | – | -1,000,000 | -100.0% | -4.53% | – |
| SGEN | Exit | Seattle Genetics Inc | $0 | – | -373,000 | -100.0% | -5.22% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Insmed Inc | 13 | Q2 2019 | 10.0% |
| Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
| Shire PLC | 9 | Q1 2018 | 13.6% |
| Immunomedics Inc | 9 | Q2 2019 | 7.8% |
| Allergan PLC | 8 | Q2 2019 | 7.6% |
| FibroGen Inc | 8 | Q3 2018 | 3.0% |
| Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
| Pfizer Inc | 7 | Q2 2017 | 19.1% |
| Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
| Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
| CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
| ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
| Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
| VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G | 2018-11-26 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.